CT引导下^125I放射性粒子植入术在不可切除胰腺癌治疗中的应用现状及展望  

Application and prospect of CT-guided ^(125)I radioactive particle implantation in treatment of unresectable pancreatic cancer

作　　者：吴维霞 周志刚[1] 邢明泉[2] Wu Weixia;Zhou Zhigang;Xing Mingquan(Radiology Department,the First Affliated Hospital of Zhengzhou University,Zhengzhou 450000,China;Changzhi Medical College,Changzhi 046000,China)

机构地区：[1]郑州大学第一附属医院放射科,450000 [2]长治医学院,山西长治450000

出　　处：《中华临床医师杂志（电子版）》2018年第3期181-184,共4页Chinese Journal of Clinicians(Electronic Edition)

摘　　要：近年来,^(125)I放射性粒子治疗不可切除胰腺癌的治疗方法,由于其具有能有效的控制肿瘤生长,缓解患者疼痛,延长患者生存期等优势,在很大程度上改善着中晚期胰腺癌患者的生存率和生活质量。CT引导下^(125)I放射性粒子植入治疗不可切除胰腺癌的临床研究不断增多,而以三维打印模板制定个体化理想合理的治疗计划系统的模式在粒子剂量选择上的应用成为研究的热点和难点,现对此方面的研究进展作一综述,期待为临床推广提供方向。In recent years, ^（125）I radioactive particle implantation has significantly improved the survival rate and quality of life in patients with unresectable pancreatic cancer, because it can effectively control tumor growth, relieve the pain of patients, and prolong the survival time of the patients. The clinical research of CT-guided ^（125）I radioactive particle implantation for the treatment of unresectable pancreatic cancer has greatly increased, and the application of 3 D printing template-based individualized treatment planning system has become a hot topic, although particle dose selection is still a challenge. In this paper, we review the progress of CT-guided ^（125）I radioactive particle implantation in the treatment of unresectable pancreatic cancer, with an aim to promote its future clinical application.

关 键 词：胰腺癌 ^125I放射性粒子 剂量学 

分 类 号：R730.55[医药卫生—肿瘤] R735.9[医药卫生—临床医学]